<DOC>
	<DOCNO>NCT00310817</DOCNO>
	<brief_summary>To compare functional immune response 28 day administration one dose Men ACWY-CRM conjugate vaccine without adjuvant ( MenACWY-CRM ( Ad- ) ) Men ACWY polysaccharide ( PS ) vaccine</brief_summary>
	<brief_title>Safety Immunogenicity Novartis Meningococcal ACWY Conjugate Vaccine Healthy Children Aged 12-59 Months .</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>healthy 12 &lt; 60 month old child ; subject previously receive meningococcal vaccine subject serious acute chronic progressive disease</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>meningitis</keyword>
	<keyword>child</keyword>
	<keyword>vaccine</keyword>
</DOC>